Stevanato Group S.p.A. (STVN)
USD 21.88
(0.3%)
USD 21.88
(0.3%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.07 Billion EUR | 24.94% |
| 2022 | 1.65 Billion EUR | 16.99% |
| 2021 | 1.41 Billion EUR | 46.54% |
| 2020 | 967.97 Million EUR | 9.73% |
| 2019 | 882.17 Million EUR | 12.87% |
| 2018 | 781.58 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.19 Billion EUR | -0.8% |
| 2024 Q1 | 2.21 Billion EUR | 6.83% |
| 2023 Q3 | 1.92 Billion EUR | 6.54% |
| 2023 Q2 | 1.8 Billion EUR | 3.76% |
| 2023 FY | 2.07 Billion EUR | 24.94% |
| 2023 Q1 | 1.74 Billion EUR | 5.04% |
| 2023 Q4 | 2.07 Billion EUR | 7.59% |
| 2022 Q3 | 1.62 Billion EUR | 5.84% |
| 2022 Q2 | 1.53 Billion EUR | 4.83% |
| 2022 FY | 1.65 Billion EUR | 16.99% |
| 2022 Q1 | 1.46 Billion EUR | 3.46% |
| 2022 Q4 | 1.65 Billion EUR | 1.92% |
| 2021 Q1 | 979.38 Million EUR | 1.18% |
| 2021 FY | 1.41 Billion EUR | 46.54% |
| 2021 Q3 | 1.38 Billion EUR | 37.67% |
| 2021 Q2 | 1 Billion EUR | 2.86% |
| 2021 Q4 | 1.41 Billion EUR | 2.28% |
| 2020 Q4 | 967.97 Million EUR | 0.0% |
| 2020 FY | 967.97 Million EUR | 9.73% |
| 2020 Q1 | - EUR | 0.0% |
| 2019 FY | 882.17 Million EUR | 12.87% |
| 2018 FY | 781.58 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alcon Inc. | 29.6 Billion USD | 92.997% |
| AptarGroup, Inc. | 4.45 Billion USD | 53.429% |
| Baxter International Inc. | 28.27 Billion USD | 92.668% |
| Becton, Dickinson and Company | 52.78 Billion USD | 96.072% |
| Bausch + Lomb Corporation | 13.44 Billion USD | 84.576% |
| Haemonetics Corporation | 2.19 Billion USD | 5.571% |
| Envista Holdings Corp | 6.6 Billion USD | 68.611% |
| ResMed Inc. | 6.87 Billion USD | 69.832% |
| Teleflex Incorporated | 7.53 Billion USD | 72.476% |
| Warby Parker Inc. | 580.31 Million USD | -257.271% |
| West Pharmaceutical Services, Inc. | 3.82 Billion USD | 45.86% |